RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull
"RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull" was originally created and published by Clinical ...
BioPharma Dive15h
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...
FiercePharma22h
Autolus readies its CAR-T Aucatzyl to go after heavy hitter competition following FDA nod
Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...
BioPharma Dive20h
FDA approves new CAR-T competitor to Gilead’s Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
Le Lézard23h
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
Lakeside Holding Limited ("Lakeside" or the "Company") , a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market operating under the brand ...
US minority veterans face unequal access to Ozempic and Wegovy, study finds
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...